Meiji Yasuda Asset Management Co Ltd. Takes $23.87 Million Position in AbbVie Inc. $ABBV

Meiji Yasuda Asset Management Co Ltd. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 94,867 shares of the company’s stock, valued at approximately $23,872,000. AbbVie comprises about 1.1% of Meiji Yasuda Asset Management Co Ltd.’s investment portfolio, making the stock its 13th largest position.

Other institutional investors also recently bought and sold shares of the company. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC boosted its position in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC boosted its position in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after acquiring an additional 43 shares during the last quarter. Fielder Capital Group LLC grew its stake in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after acquiring an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC raised its holdings in AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock valued at $751,000 after acquiring an additional 44 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

ABBV stock opened at $261.50 on Thursday. The firm has a market cap of $462.02 billion, a PE ratio of 73.87, a PEG ratio of 1.18 and a beta of 0.29. The firm’s 50 day moving average price is $254.23 and its 200-day moving average price is $229.67. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio is presently 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ABBV. Barclays raised their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Cantor Fitzgerald upped their target price on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Finally, Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.